longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Bayer Aktiengesellschaft

BAYZF

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -27.57, below the reasonable range, cheaper than 93.02% of the time in the past 5 years, and the industry ranks 209/257, the industry Median -1.46.

-27.57xP/E
$56.61Stock price
$-2.05Earnings per share
-27.57xP/E
Stock price$56.61Earnings per share$-2.05

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-8.58x
Typical range
-20.47x–19.74x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0306090120

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-57.34x149.86%$59.87B
BAYZFUSBayer Aktiengesellschaft
-27.57x--$55.62B
BAYRYUSBayer
-27.62x--$55.72B
VTRSUSViatris
-48.05x107.75%$19.73B
ELANUSElanco Animal Health
-57.57x129.36%$11.46B
VREOFUSVIREO GROWTH INC
-169.84x--$11.40B
AXSMUSAxsome Therap
-55.51x26.60%$10.64B
CURLFUSCuraleaf Holdings, Inc.
-170.67x--$8.88B
BLTEUSBelite Bio
-68.99x29.87%$7.06B
DFTXUSDefinium Therapeutics
-15.31x53.61%$5.42B
MANEUSVeraDermics
-47.33x97.44%$4.94B
EWTXUSEdgewise Therapeutics
-24.51x137.29%$4.83B
AMLXUSAmylyx Pharmaceuticals
-27.23x1.76%$4.14B
ELVNUSEnliven Therapeutics
-33.33x1.17%$3.53B
TARSUSTarsus Pharmaceuticals
-72.78x34.09%$3.38B
RGCUSRegencell Bioscience
-437.93x--$3.09B
MBXUSMBX Biosciences
-28.62x30.54%$2.98B
GPCRUSStructure Therapeutics
-12.25x104.48%$2.63B
SUPNUSSupernus Pharma
-23.14x70.59%$2.54B
PHVSUSPharvaris BV
-12.45x7.70%$2.47B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.